2025
SJR Q1
JCR Q1 · 7
6 eşleşen makale
SCIE
Dergi ayrıntısı
CNS Drugs
- Ülke
- Switzerland · Western Europe
- Tür
- journal
- ISSN
-
1172704711791934
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 2,161
- Quartile Q1
- H-Index 140
- Atıf/yayın 7,56
- Doküman (3y) 234
- Atıf (3y) 1.854
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 7
- 5Y JIF 7,9
- JCI 1,64
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Neurology (clinical) Q1
- Pharmacology (medical) Q1
- Psychiatry and Mental Health Q1
Alanlar
- Medicine
WoS kategorileri
- Clinical Neurology | Pharmacology & Pharmacy | Psychiatry
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 2,161 | 7 | 7,9 | 1,64 | Q1 | 140 |
| 2024 | Q1 | Q1 | 1,884 | 7,4 | 7 | 1,58 | Q1 | 132 |
| 2023 | Q1 | Q1 | 1,616 | 7,4 | 6,4 | 1,46 | Q1 | 132 |
| 2022 | Q1 | Q1 | 1,485 | 6 | 6,2 | 1,26 | Q1 | 132 |
| 2021 | Q1 | Q1 | 1,263 | 6,5 | 6,5 | 1,24 | Q1 | 132 |
| 2020 | Q1 | Q1 | 1,565 | 5,8 | 5,9 | 1,23 | Q1 | 132 |
| 2019 | Q1 | Q1 | 1,522 | 4,8 | 4,8 | 1,19 | Q1 | 132 |
| 2018 | — | Q1 | — | 4,2 | 4,6 | 1,15 | Q1 | — |
| 2017 | Q1 | Q1 | 1,635 | 4,2 | 4,4 | 1,15 | Q1 | 132 |
| 2016 | Q1 | Q1 | 1,819 | 4,4 | 4,8 | — | — | 132 |
| 2015 | Q1 | Q1 | 1,767 | 4,9 | 4,7 | — | — | 132 |
| 2014 | Q1 | Q1 | 1,922 | 5,1 | 5 | — | — | 132 |
| 2013 | Q1 | Q1 | 1,727 | 4,4 | 4,6 | — | — | 132 |
| 2012 | Q1 | Q1 | 1,921 | 4,8 | 4,6 | — | — | 132 |
| 2011 | Q1 | Q1 | 1,557 | 4,8 | 4,3 | — | — | 132 |
| 2010 | Q1 | Q1 | 1,518 | 4,5 | 4,4 | — | — | 132 |
| 2009 | — | Q1 | — | 3,9 | 4,1 | — | — | — |
| 2008 | — | Q1 | — | 3,8 | 4,3 | — | — | — |
| 2007 | — | Q1 | — | 4,5 | 4,3 | — | — | — |
| 2006 | — | Q1 | — | 4,2 | — | — | — | — |
| 2005 | — | Q1 | — | 3,7 | — | — | — | — |
| 2004 | — | Q1 | — | 4,2 | — | — | — | — |
| 2003 | — | Q1 | — | 3,8 | — | — | — | — |
| 2002 | — | Q2 | — | 1,8 | — | — | — | — |
| 2001 | — | Q3 | — | 1,3 | — | — | — | — |
| 2000 | — | Q2 | — | 1,6 | — | — | — | — |
| 1999 | — | Q2 | — | 1,5 | — | — | — | — |
| 1998 | — | Q1 | — | 1,8 | — | — | — | — |
| 1997 | — | Q2 | — | 1,7 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 24/296 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 33/356 |
| 2025 | PSYCHIATRY | SCIE | Q1 | Q1 | 22/293 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 21/286 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 22/352 |
| 2024 | PSYCHIATRY | SCIE | Q1 | Q1 | 14/288 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 17/280 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 14/354 |
| 2023 | PSYCHIATRY | SCIE | Q1 | Q1 | 14/279 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 28/212 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 36/278 |
| 2022 | PSYCHIATRY | SCIE | Q1 | Q1 | 37/155 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 30/212 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 42/279 |
| 2021 | PSYCHIATRY | SCIE | Q1 | Q1 | 38/155 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 36/208 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 46/276 |
| 2020 | PSYCHIATRY | SCIE | Q1 | Q1 | 27/156 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 34/204 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 34/271 |
| 2019 | PSYCHIATRY | SCIE | Q1 | Q1 | 23/155 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 42/199 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 46/267 |
| 2018 | PSYCHIATRY | SCIE | Q1 | Q1 | 31/146 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 38/197 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 37/261 |
| 2017 | PSYCHIATRY | SCIE | Q1 | Q1 | 27/142 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 33/194 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/257 |
| 2016 | PSYCHIATRY | SCIE | Q1 | — | 25/142 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 20/193 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 21/255 |
| 2015 | PSYCHIATRY | SCIE | Q1 | — | 21/142 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 18/192 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 19/255 |
| 2014 | PSYCHIATRY | SCIE | Q1 | — | 19/140 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 27/194 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 28/256 |
| 2013 | PSYCHIATRY | SCIE | Q1 | — | 23/136 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 20/193 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 24/261 |
| 2012 | PSYCHIATRY | SCIE | Q1 | — | 19/135 |
| 2011 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 20/192 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 26/261 |
| 2011 | PSYCHIATRY | SCIE | Q1 | — | 16/130 |
| 2010 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 26/185 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 31/252 |
| 2010 | PSYCHIATRY | SCIE | Q1 | — | 19/128 |
| 2009 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 25/167 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 45/237 |
| 2009 | PSYCHIATRY | SCIE | Q1 | — | 23/117 |
| 2008 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 23/156 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 44/219 |
| 2008 | PSYCHIATRY | SCIE | Q2 | — | 26/101 |
| 2007 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 14/146 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 23/205 |
| 2007 | PSYCHIATRY | SCIE | Q1 | — | 12/94 |
| 2006 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 18/147 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 29/199 |
| 2006 | PSYCHIATRY | SCIE | Q1 | — | 15/94 |
| 2005 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 19/148 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 35/193 |
| 2005 | PSYCHIATRY | SCIE | Q1 | — | 18/94 |
| 2004 | NEUROSCIENCES | SCIE | Q1 | — | 34/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 26/187 |
| 2003 | NEUROSCIENCES | SCIE | Q1 | — | 39/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 27/185 |
| 2002 | NEUROSCIENCES | SCIE | Q3 | — | 107/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 75/188 |
| 2001 | NEUROSCIENCES | SCIE | Q3 | — | 125/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 98/186 |
| 2000 | NEUROSCIENCES | SCIE | Q3 | — | 110/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 75/181 |
| 1999 | NEUROSCIENCES | SCIE | Q3 | — | 113/201 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/175 |
| 1998 | NEUROSCIENCES | SCIE | Q2 | — | 89/202 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 43/178 |
| 1997 | NEUROSCIENCES | SCIE | Q3 | — | 84/150 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 46/157 |